返回 Agenda
Microbiome: Innovative Therapeutics, Challenges, and Opportunities
Session Chair(s)
Caroline B. Kurtz, PHD
Head of Translational Science and Product Development
Synlogic, United States
Emerging research points to the significant role of microbiome in contributing to disease and how promoting maintenance of a “healthy microbiome” across a wide variety of disease states can maintain health, prevent, intercept, and treat disease states. How do we handle the complexity of the microbiome in conducting clinical research and monitoring? Does addressing the microbiome impact how we view disease and clinical practice? Do we need new regulatory and medical approaches to manage?
Learning Objective : Describe the complexity of the microbiome in both health and disease management; Identify how addressing the microbiome can fundamentally change our approach to medicine.
Speaker(s)
Overview of the Microbiome and Approaches to Therapeutic Development
Caroline B. Kurtz, PHD
Synlogic, United States
Head of Translational Science and Product Development
Regulatory Aspects of Microbiome Product Development
James R. Weston, MBA
Seres Therapeutics, Inc., United States
Vice President, Regulatory Affairs
Clinical Development Challenges for Microbiome Drug Development
Paul K. Plumb
Rebiotix, Inc. , United States
Head of Clinical Operations